GENETIC ENGINEERING TECHNOLOGIES The Genetic Engineering Technologies Shared Resource (GET) provides JAX Cancer Center (JAXCC) members with all-inclusive access to the technical expertise, instrumentation, and centralized facilities necessary to engineer and produce complex, precisely tunable, genetically engineered mouse models of cancer. Genetic manipulation of the mouse genome and the production of novel genomic variants has been critical for evaluating gene function in an organismal context. Unfortunately, many strains have been recalcitrant to genetic engineering owing to their reproductive biology constraints and inefficiencies with the methods that induce the gene modification. Thus, to produce next-generation mouse models, these limitations must be overcome by combining optimal genetic background (i.e., strain) with the ability to engineer single, or multiple, genomic variants with high efficiency in a cost-effective manner. Through the integration of molecular construct development, cell biology, microinjection and viral vector expertise, GET is capable of taking a project from conception to delivery of live mice with transient or germline-transmissible engineered mutations. On behalf of the JAXCC members, GET performs the associated genetic engineering approaches, including allele design, gene-editing reagent synthesis and QC, genotyping assay development, and mouse zygote or ES cell gene- editing manipulation with modern targeted nuclease technology (CRISPR/Cas). The group has extensive experience (>1000 CRISPR/Cas gene editing projects) and success generating genetically modified mice on over 100 different inbred and specialty strains, and provides all the necessary husbandry to produce and validate newly engineered mouse models. The design and production of high-titer viral vector preparations enable JAXCC members to create somatic transgenesis mouse models that complement germline mutant models. Staff within all components of GET provide consultation and experimental design support with gene engineering specialists, as well as support for animal care and use, biosafety and biosecurity applications, training, and provision of tested reagents and supplies for those investigators who choose to carry out aspects of the genetic engineering and cell biology processes in their own laboratories.
Our Specific Aims are to: 1) Provide a comprehensive, precise genome engineering service capable of generating germline-transmissible alleles not limited by the mouse strain of origin; 2) Provide comprehensive recombinant virus genome engineering tools for introducing precise genetic modifications in mammalian cells; and 3) Provide molecular, cellular or embryological tools for gene engineering or target validation processes for JAXCC members. Execution of these aims in a centralized resource provides a cost effective, scalable, and precise genome engineering platform as well as the technical and operational experience no single research laboratory could effectively create and maintain. This is the value of GET for the JAXCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-34
Application #
9854059
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
34
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Richter, Wolfgang F; Christianson, Gregory J; Frances, Nicolas et al. (2018) Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. MAbs 10:803-813
Tamura, Ryo; Yoshihara, Kosuke; Saito, Tetsuya et al. (2018) Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis 7:4
Rutherford, Sarah C; Fachel, Angela A; Li, Sheng et al. (2018) Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood 132:e13-e23
Barthel, Floris P; Wesseling, Pieter; Verhaak, Roel G W (2018) Reconstructing the molecular life history of gliomas. Acta Neuropathol 135:649-670
Kim, Hyunsoo; Kumar, Pooja; Menghi, Francesca et al. (2018) High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci Rep 8:17937
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Barthel, Floris P; Johnson, Kevin C; Wesseling, Pieter et al. (2018) Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurol Clin 36:421-437
Schechter, Lisa M; Creely, David P; Garner, Cherilyn D et al. (2018) Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli. MBio 9:
Tarchini, Basile; Longo-Guess, Chantal; Tian, Cong et al. (2018) A spontaneous mouse deletion in Mctp1 uncovers a long-range cis-regulatory region crucial for NR2F1 function during inner ear development. Dev Biol 443:153-164
Vian, Laura; P?kowska, Aleksandra; Rao, Suhas S P et al. (2018) The Energetics and Physiological Impact of Cohesin Extrusion. Cell 173:1165-1178.e20

Showing the most recent 10 out of 1156 publications